RLMD
Relmada Therapeutics, Inc. · Healthcare
Director Paul Edward Kelly bought $135K of Relmada Therapeutics, Inc.
Bought$135,000
$0.90Price
150,000Shares
+64%Stake
What RLMD did for a copier
Prices for RLMD after this filing aren't in yet.
Paul Edward Kelly's record
3 other buys with 3 months of prices since 2019: on average −18.3% against the S&P 500, and 1 of 3 beat it.
We're building an app that can copy buys like this into your own brokerage. Join the waitlist
Traded Fri, Oct 12. Filed Fri, Oct 19, 9:02 AM ET, before the open. Not investment advice.